1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Medrx Co., Ltd.

Medrx Co., Ltd.

TTSE:4586
52.00
JPY
+1.00
(+1.96%)
3.31BMarket Cap
Nov 13Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
12.51
3.93
5.62
2.76
23.12
0.84
14.12
7.08
0.39
2.35
0.85
5.93
2.38
- -
Basic EPS, GAAP
-113.48
-151.96
-131.21
-155.48
-103.15
-126.77
-134.32
-68.61
-49.62
-43.81
-26.82
-18.56
-17.44
- -
Free Cash Flow per Basic Share
-124.73
-156.1
-123.65
-150.89
-105.54
-130.33
-149.55
-63.08
-43.37
-42.39
-26.3
-18.49
-18.07
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
673.08
525.3
402.41
294.37
228.81
208.59
140.06
110.5
79.51
42.97
50.17
45.69
34.52
26.42
Tangible Book Value per Share
672.9
524.88
402.11
294.22
228.74
208.59
140.06
110.5
79.51
42.97
50.17
45.69
34.52
26.42
Basic Weighted Avg Shares
5
7
7
8
9
10
12
16
21
25
35
43
54
58
Sales/Revenue/Turnover
69
26
38
22
198
8
170
115
8
59
30
258
128
- -
Operating Margin (%)
-882.06
-3,816.64
-2,658.65
-6,010.42
-496.14
-15,164.59
-958.42
-982.19
-12,709.29
-1,847.32
-3,160.99
-307.48
-735.45
- -
Depreciation Expense
28
52
76
58
59
40
40
56
60
46
46
38
14
- -
Net Income, GAAP
-622
-1,017
-878
-1,259
-884
-1,268
-1,616
-1,115
-1,060
-1,111
-933
-807
-937
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-907.03
-3,867.4
-2,335.33
-5,635.74
-446.18
-15,096.89
-951.56
-968.48
-12,692.61
-1,868.04
-3,158.72
-312.8
-731.84
- -
Working Capital
3,850
2,775
2,094
2,633
1,748
1,768
1,385
1,764
1,629
929
1,685
1,967
1,748
1,246
LT Debt
- -
- -
- -
395
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
4,503
3,514
2,772
2,507
2,034
2,131
1,921
2,147
1,955
1,213
1,925
2,170
2,049
1,592
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-26.04
-25.36
-27.94
-47.7
-38.95
-60.88
-79.79
-54.8
-51.66
-70.14
-59.47
-39.4
-44.44
- -

Capital Structure

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
44
59
60
Market Capitalization
7,910
6,352
3,315

Working Capital

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
Total Current Assets
2,228
- -
1,343
Cash, Cash Equivalents & STI
2,166
- -
1,143
Accounts Receivable, Net
2
- -
- -
Inventories
12
- -
40
Total Current Liabilities
42
- -
97
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.28%
3.79%
-5.58%
Free Cash Flow
6.09%
0.04%
20.8%
Net Income, GAAP
3.99%
-2.69%
16.19%
Sales/Revenue/Turnover
373.37%
238.44%
-50.34%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
231
- -
- -
258
2025
- -
- -
- -
- -
128
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-3.33
1.53
- -
- -
-18.56
2025
- -
- -
- -
- -
-17.44
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yonehiro Matsumura
Full Time Employees
21
Sector
Health technology
Industry
Pharmaceuticals: major
Address
431-7 Nishiyama Higashikagawa KA Japan 769-2712
IPO Date
Feb 13, 2013
Website
medrx.co.jp
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
MedRx Co., Ltd. MedRx Co., Ltd engages primarily in the research, development, and formulation of pharmaceutical products utilizing advanced transdermal absorption technologies in Japan. The company develops innovative medicines based on its proprietary Ionic Liquid Transdermal System (ILTS) and Nano-sized Colloid Transdermal System (NCTS), which enhance drug solubility, absorbability, and efficacy while minimizing side effects and enabling administration for patients unable to take oral medications; its product pipeline includes MRX-4TZT in phase I clinical trials for spastic paralysis, MRX-9FLT in phase I for chronic, cancer, and severe pain, MRX-7MLL and MRX-6LDT in preclinical stages for Alzheimer’s disease and chronic pain, and MRX-5LBT that has completed clinical trials for postherpetic neuralgia, alongside efforts in painless transdermal delivery for vaccines, nucleic acid medicines, protein medicines, and microneedle array patch vaccines. MedRx Co., Ltd. also explores oral formulations using ionic liquid systems to improve absorbability of challenging active pharmaceutical ingredients (APIs) and seeks partnering opportunities for novel therapies. Founded in 2002 and headquartered in Higashikagawa, Japan, the company operates mainly in the pharmaceuticals sector with a focus on specialty transdermal and advanced drug delivery systems targeting nervous system disorders, pain management, and other unmet medical needs. Recent developments include a 2017 worldwide licensing agreement (excluding East Asia) with Cipla USA Inc. for MRX-4TZT, providing up to USD 30 million in milestone payments and tiered royalties, and a March 2025 private placement of 118,700 units of its 32nd Series Stock Acquisition Rights to raise funds for ongoing operations and development.